Patents by Inventor Catherine Leblanc

Catherine Leblanc has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS
    Publication number: 20140243346
    Abstract: The present invention provides heterocyclic derivatives which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharmaceutical compositions comprising such derivatives are also encompassed. Examples of compounds of the invention include the compounds according to Formula Ia, or a pharmaceutically acceptable salt thereof, and the compounds of the examples.
    Type: Application
    Filed: April 30, 2014
    Publication date: August 28, 2014
    Applicant: NOVARTIS AG
    Inventors: Steven John CHARLTON, Catherine LEBLANC, Stephen Carl McKEOWN
  • Bacterial Iodoperoxidases from Zobellia Galactanivorans, Methods of Preparation and Uses Thereof
    Publication number: 20140212931
    Abstract: The present invention concerns iodoperoxidases from Zobellia galactanivorans, isolated nucleic acids encoding same, as well as methods for preparing these enzymes. Moreover, the invention is also directed to the use of such iodoperoxidases in a wide range of industrial, pharmaceutical, medical, cosmetics, and ecological applications, as well as in the food industry.
    Type: Application
    Filed: July 5, 2012
    Publication date: July 31, 2014
    Applicants: Universite Pierre et Marie Curie (Paris 6), Centre National de la Recherche Scientifique (CNRS)
    Inventors: Catherine Leblanc, Ludovic Delage, Gurvan Michel, Etienne Rebuffet, Mirjam Czjzek, Philippe Potin
  • Pyrrolopyridine derivatives and their use as CRTH2 antagonists
    Patent number: 8791256
    Abstract: There are provided according to the invention compounds of formula (I) in free or salt form, wherein R1, R2, R3, R4, R5, R6, Q, W, X, m, n and p are as described in the specification, process for preparing them, and their use as pharmaceuticals.
    Type: Grant
    Filed: June 5, 2013
    Date of Patent: July 29, 2014
    Assignee: Novartis AG
    Inventors: Kamlesh Jagdis Bala, Catherine Leblanc, David Andrew Sandham, Katharine Louise Turner, Simon James Watson, Lyndon Nigel Brown, Brian Cox
  • Pyrido[2,3-b]pyrazine compounds useful as IP receptor agonist
    Patent number: 8754085
    Abstract: The present invention provides heterocyclic derivatives which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharmaceutical compositions comprising such derivatives are also encompassed. Examples of compounds of the invention include the compounds according to Formula Ia, or a pharmaceutically acceptable salt thereof, and the compounds of the examples.
    Type: Grant
    Filed: July 14, 2011
    Date of Patent: June 17, 2014
    Assignee: Novartis AG
    Inventors: Steven John Charlton, Catherine Leblanc, Stephen Carl McKeown
  • PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS
    Publication number: 20130267518
    Abstract: There are provided according to the invention compounds of formula (I) in free or salt form, wherein R1, R2, R3, R4, R5, R6, Q, W, X, m, n and p are as described in the specification, process for preparing them, and their use as pharmaceuticals.
    Type: Application
    Filed: June 5, 2013
    Publication date: October 10, 2013
    Inventors: Kamlesh Jagdis Bala, Catherine Leblanc, David Andrew Sandham, Katherine Louise Turner, Simon James Watson, Lyndon Nigel Brown, Brian Cox
  • Organic compounds
    Patent number: 8470848
    Abstract: There are provided according to the invention compounds of formula (I), in free or salt form, wherein R1, R2, R3, R4, R5, R6, Q, W, X, m, n and p are as described in the specification, process for preparing them, and their use as pharmaceuticals.
    Type: Grant
    Filed: February 3, 2010
    Date of Patent: June 25, 2013
    Assignee: Novartis AG
    Inventors: Kamlesh Jagdis Bala, Catherine Leblanc, David Andrew Sandham, Katharine Louise Turner, Simon James Watson, Lyndon Nigel Brown, Brian Cox
  • Pyrrolopyridine derivatives and their use as CRTH2 antagonists
    Patent number: 8455645
    Abstract: There are provided according to the invention compounds of formula (I), in free or salt form, wherein R1, R2, R3, R4, R5, R6, Q, W, X, m, n and p are as described in the specification, process for preparing them, and their use as pharmaceuticals.
    Type: Grant
    Filed: February 3, 2010
    Date of Patent: June 4, 2013
    Assignee: Novartis AG
    Inventors: Kamlesh Jagdis Bala, Catherine Leblanc, David Andrew Sandham, Katharine Louise Turner, Simon James Watson, Lyndon Nigel Brown, Brian Cox
  • Pyrrolopyridine compounds and their use in treating disease
    Patent number: 8431703
    Abstract: There are provided according to the invention compounds of formula (I) in free ors salt form, wherein R1, R2, R4, R5, R6, A, D, X, W, m and n are as described in the specification, process for preparing them, and their use as pharmaceuticals.
    Type: Grant
    Filed: December 7, 2006
    Date of Patent: April 30, 2013
    Assignee: Novartis AG
    Inventors: David Andrew Sandham, Catherine Leblanc, Lyndon Nigel Brown
  • Organic compounds
    Patent number: 8431578
    Abstract: Compounds of formula (I) in free or salt or solvate form, where T1, T2, and T3 have the meanings as indicated in the specification, are useful for treating inflammatory or obstructive airways, pulmonary hypertension, pulmonary fibrosis, liver fibrosis, muscle diseases and systemic skeletal disorders. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Grant
    Filed: January 9, 2009
    Date of Patent: April 30, 2013
    Assignee: Novartis AG
    Inventors: Peter Hunt, Catherine Leblanc, Robert Alexander Pulz, Nikolaus Johannes Stiefl
  • IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS
    Publication number: 20130102611
    Abstract: The present invention provides heterocyclic derivatives which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharmaceutical compositions comprising such derivatives are also encompassed. Examples of compounds of the invention include the compounds according to Formula Ia, or a pharmaceutically acceptable salt thereof, and the compounds of the examples.
    Type: Application
    Filed: July 14, 2011
    Publication date: April 25, 2013
    Applicant: Novartis AG
    Inventors: Steven John Charlton, Catherine Leblanc, Stephen Carl McKeown
  • Organic compounds
    Patent number: 8367662
    Abstract: Compounds of formula I: in free or salt or solvate form, where R1, R2, R3 and R20 have the meanings as indicated in the specification, are useful for treating diseases mediated by the ALK-5 and/or ALK-4 receptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described. These compounds are useful for the treatment of inflammatory or obstructive airways diseases such as pulmonary hypertension, pulmonary fibrosis, liver fibrosis, cancer, muscle diseases such as muscle atrophies and muscle dystrophies, and systemic skeletal disorders such as osteoporosis.
    Type: Grant
    Filed: October 15, 2008
    Date of Patent: February 5, 2013
    Assignee: Novartis AG
    Inventors: Duncan Shaw, Catherine Leblanc, Dimitrios Lizos, Cathy Ritchie, Vikki Furminger, Sarah Lewis, Benoit Hornsperger, Nikolaus Johannes Stiefl, Sven Weiler
  • Organic compounds
    Patent number: 8343966
    Abstract: Compounds of formula I in free or salt or solvate form, where T1, T2, X, Ra, Rb, R8 and R9 have the meanings as indicated in the specification, are useful for treating inflammatory or obstructive airways, pulmonary hypertension, pulmonary fibrosis, liver fibrosis, muscle diseases and systemic skeletal disorders. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Grant
    Filed: January 2, 2009
    Date of Patent: January 1, 2013
    Assignee: Novartis AG
    Inventors: Claire Adcock, Urs Baettig, Peter Hunt, Catherine Leblanc, Maude Nadine Pierrette Pipet, Robert Alexander Pulz, Katrin Spiegel, Nikolaus Johannes Stiefl
  • Pyrrolopyrimidines and pyrrolopyridines
    Patent number: 8314112
    Abstract: Compounds of formula I in free or salt or solvate form, wherein X, T1, T3 and T4 have the meanings as indicated in the specification, are useful for treating diseases mediated by the ALK-5 and/or ALK-4 receptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Grant
    Filed: January 9, 2009
    Date of Patent: November 20, 2012
    Assignee: Novartis AG
    Inventors: Catherine Leblanc, Robert Alexander Pulz, Nikolaus Johannes Stiefl
  • 5-phenylthiazole derivatives and use as PI3 kinase inhibitors
    Patent number: 8129541
    Abstract: Compounds of formula I in free or salt form, wherein R1, R2, R3, R4 and R5 have the meanings as indicated in the specification, are useful for treating diseases mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Grant
    Filed: December 17, 2009
    Date of Patent: March 6, 2012
    Assignee: Novartis AG
    Inventors: Ian Bruce, Peter Finan, Catherine LeBlanc, Clive McCarthy, Lewis Whitehead, Nicola Press, Graham Charles Bloomfield, Judy Hayler, Louise Kirman, Mrinalini Sachin Oza, Lena Shukla
  • 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors
    Patent number: 8017608
    Abstract: Compounds of formula I in free or salt form, wherein R1, R2, R3, R4 and R5 have the meanings as indicated in the specification, are useful for treating diseases mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Grant
    Filed: March 5, 2004
    Date of Patent: September 13, 2011
    Assignee: Novartis AG
    Inventors: Graham Charles Bloomfield, Ian Bruce, Catherine Leblanc, Mrinalini Sachin Oza, Lewis Whithead, Bernard Cuenoud, Thomas Hugo Keller, Louise Kirman, Clive McCarthy, Gaynor Elizabeth Woodward
  • Pyrimidine derivatives as alk-5 inhibitors
    Patent number: 7989458
    Abstract: Compounds of formula (I) in free or salt or solvate form, where T1, T2, Ra and Rb have the meanings as indicated in the specification, are useful for treating inflammatory or obstructive airways, pulmonary hypertension, pulmonary fibrosis, liver fibrosis, muscle diseases and systemic skeletal disorders. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Grant
    Filed: July 12, 2007
    Date of Patent: August 2, 2011
    Assignee: Novartis AG
    Inventors: Catherine Leblanc, Maude Nadine Pierrette Pipet, Robin Alec Fairhurst, Claire Adcock, Robert Alexander Pulz, Duncan Shaw, Nikolaus Johannes Stiefl
  • 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES
    Publication number: 20110124624
    Abstract: Compounds of Formula I: in free or salt form, wherein Ra, Rb, R2, R3, R4 and R5 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.
    Type: Application
    Filed: February 3, 2011
    Publication date: May 26, 2011
    Inventors: Graham Charles Bloomfield, Ian Bruce, Judy Fox Hayler, Catherine LeBlanc, Darren Mark Le Grand, Clive McCarthy
  • 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES
    Publication number: 20110124693
    Abstract: Compounds of Formula I: in free or salt form, wherein Ra, Rb, R2, R3, R4 and R5 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.
    Type: Application
    Filed: February 3, 2011
    Publication date: May 26, 2011
    Inventors: Graham Charles Bloomfield, Ian Bruce, Judy Fox Hayler, Catherine Leblanc, Darren Mark Le Grand, Clive McCarthy
  • Imidazo-Pyridine Derivatives as Activin-Like Receptor Kinase (ALK4 or ALK5) Inhibitors
    Publication number: 20110060004
    Abstract: Compounds of formula (I): in free or salt or solvate form, where X, R1, R2, R3 and R4 have the meanings as indicated in the specification, are useful for treating diseases mediated by the ALK-5 and/or ALK-4 receptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Application
    Filed: April 27, 2009
    Publication date: March 10, 2011
    Applicant: NOVARTIS AG
    Inventors: Catherine Leblanc, Ritchie Cathy, Duncan Shaw, Nikolaus Johannes Stiefl
  • 5-phenyl-4-methyl-thiazol-2-yl-amine derivatives as inhibitors of phosphatidylin ositol 3 kinase enzymes (PI13) for treatment of inflammatory diseases
    Patent number: 7902375
    Abstract: in free or salt form, wherein Ra, Rb, R2, R3, R4 and R5 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.
    Type: Grant
    Filed: August 27, 2004
    Date of Patent: March 8, 2011
    Assignee: Novartis AG
    Inventors: Graham Charles Bloomfield, Ian Bruce, Judy Fox Hayler, Catherine Leblanc, Darren Mark Le Grand, Clive McCarthy